Studies comparing aggressive hydration with lactate Ringer plus indomethacin: results
| Author (country, year) [ref] | PEP (%) (experimental vs. control arm) | Severe PEP (%) | Hyperamylasemia (%) | Isolated pancreatic pain (%) | Fluid overload | Others SAE (serious adverse events between groups) | Pancreatic stent (%) |
|---|---|---|---|---|---|---|---|
| Mok et al. (USA, 2017) [47] | 6 vs. 21 vs. 13 vs. 19 | 0 vs. 0 vs. 2 vs. 0 | NA | NA | Only 1 patient in NSS + placebo group | None | 21 vs. 31 vs. 25 vs. 31 |
| Hajalikhani et al. (Iran, 2018) [48] | 0.9 vs. 2.7 (p = 0.622) | No severe PEP in the groups | 0.9 vs. 3.6 (p = 0.369) | NA | NA | NA | 2.8 vs. 2.7 |
| Thanage et al. (India, 2021) [49] | 10.5 vs. 15.7 vs. 14.0 | 1 patient in diclofenac group | NA | NA | 2 pts in LR + diclofenac arm1 in LR arm | NA | 10.5 vs. 7 vs. 3.5 |
| Boal Carvalho et al. (Portugal, 2022) [50] | 3.6 vs. 13.9 (p = 0.021) | 0 vs. 6.9 (p = 0.020) | 4.5 vs. 10.3 | NA | None | None | 16.9 vs. 16.7 |
| Sperna Weiland et al. (Netherlands, 2021) [51] | 8 vs. 9 (p = 0.53) | 5 vs. 8 (p = 0.23)°, 1 vs. 2 (p = 0.089)§ | NA | NA | 8 pts in experimental arm, 9 in control arm | None | 6 vs. 6 |
§ Atlanta Criteria; °: Cotton Criteria; LR: lactated Ringer’s; NA: not available; NSS: normal saline solution; PEP: post-ERCP acute pancreatitis; pts: patients